케이바이오랩스

038530KOSDAQ

57.5 / 100

Reference Date: 2026-09-08

Financial Score25.0 / 40

News Sentiment12.5 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 4.0% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

KEBIO operates in two main sectors: bio-distribution of life science equipment and reagents, and ICT solutions including hardware, software, and IT services. Since acquiring CureBio's distribution division in 2021, the company has expanded its bio-distribution business, leveraging over 20 years of experience. Additionally, it is broadening its ICT offerings by developing IoT-based security solutions, such as large-scale integrated control systems and smart policing services, building on its expertise in video security technology.

Number of Employees

38people

Average Salary

49.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.25Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-4.82Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

0.33Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲97.1% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲166.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -8.8% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position6.0Point

52w upper range (61%)

Current 999Won52-week high 1,48252-week low 225

1-month return2.0Point

1m -4.03% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

11 totalPositive 0Neutral 11Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-04
Neutral주식등의대량보유상황보고서(일반)2026-09-04
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-28
Neutral주식등의대량보유상황보고서(일반)2026-08-28
Neutral주권매매거래정지 (주식의 병합, 분할 등 전자등록 변경, 말소)2026-08-24